4-butyrolactone has been researched along with palbociclib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Contreras, JI; Karpf, AR; Kizhake, S; Kour, S; Natarajan, A; Rana, S; Robb, CM; Sonawane, YA; Zahid, M | 1 |
1 other study(ies) available for 4-butyrolactone and palbociclib
Article | Year |
---|---|
Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.
Topics: 4-Butyrolactone; Amines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Female; Humans; Molecular Targeted Therapy; NF-kappa B; Ovarian Neoplasms; Piperazines; Piperidines; Prodrugs; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Sesquiterpenes; Signal Transduction; Structure-Activity Relationship | 2020 |